Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bayer Q2 misses forecasts as costs, forex effects bite

Published 08/05/2021, 01:52 AM
Updated 08/05/2021, 06:21 AM
© Reuters. FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen, Germany February 27, 2020.    REUTERS/Wolfgang Rattay/File Photo

© Reuters. FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen, Germany February 27, 2020. REUTERS/Wolfgang Rattay/File Photo

By Christoph Steitz

FRANKFURT (Reuters) - Bayer (OTC:BAYRY) shares fell to their lowest levels in more than seven months after the German agricultural and pharmaceuticals group reported lower-than-expected second-quarter core earnings due to higher production costs and currency headwinds.

Second-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) before special items fell 10.6% to 2.58 billion euros ($3.05 billion), missing the 2.79 billion forecast analysts had expected on average.

Shares in the group fell by as much as 6.1% to the bottom of the DAX, hitting their lowest since Dec. 21, 2020, after second-quarter adjusted EBITDA at Bayer's Crop Science division declined by more than a quarter.

"Higher prices and volumes, along with contributions from ongoing efficiency programmes only partly offset an increase in costs," Bayer said in a statement.

Barclays (LON:BARC) analysts said investors might be concerned by the impact of cost inflation at the Crop Science division, which includes the Roundup weedkiller brand Bayer acquired as part of the $63 billion takeover of Monsanto (NYSE:MON).

The decline in core earnings overshadowed Bayer's lifted full-year outlook, following stronger sales of prescription medicines that recovered from restrictions related to the COVID-19 pandemic.

Bayer expects sales of 43 billion euros this year, up from 41 billion earlier. EBITDA before special items is seen at 10.6 billion to 10.9 billion euros, compared with 10.5 billion to 10.8 billion previously.

The more optimistic outlook was partly driven by Bayer's pharmaceuticals division, where second-quarter sales rose 16.2% and which is being strengthened by the acquisition of Vividion Therapeutics for up to $2 billion.

"Vividion's unique technologies and special expertise will significantly strengthen our drug discovery capabilities," Bayer Chief Executive Werner Baumann said in a statement.

Bayer last week said it would book additional provisions of $4.5 billion related to litigation, which alleges that Roundup can cause cancer, bringing the total to $16.1 billion.

© Reuters. FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen, Germany February 27, 2020.    REUTERS/Wolfgang Rattay/File Photo

Bayer said it would file in August a petition with the U.S. Supreme Court seeking a review of a lower court ruling that went in favour of Roundup user Edwin Hardeman.

($1 = 0.8451 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.